Corcept Therapeutics Inc (CORT) Stock Analysis
Verdict: WATCH (do not buy)
Relacorilant approval potential drives high growth expectations, but a TTM P/E of 215x and severe insider selling leave zero margin for error.
Investment score: 43/100
Analysis as of
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Corcept Therapeutics Inc opportunities and risks
What speaks for CORT
- Relacorilant approval could double revenue to $1.59B by 2027
What speaks against CORT
- Extreme valuation multiple leaves zero safety margin for clinical delays
Frequently asked questions about Corcept Therapeutics Inc (CORT)
Is CORT stock a good investment?
The TradeMates model rates Corcept Therapeutics Inc as WATCH (do not buy) with an investment score of 43/100. Relacorilant approval potential drives high growth expectations, but a TTM P/E of 215x and severe insider selling leave zero margin for error. This is algorithmic model output, not personal investment advice.
Is CORT stock a buy?
The TradeMates model verdict for CORT is WATCH (do not buy) with an investment score of 43/100. Treat this as a model signal to review, not a personal buy recommendation.